Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2016

19.08.2016 | Review Article

Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes

verfasst von: Olga Golubnitschaja, Krishna Chander Sridhar

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Liver cancer, one of the leading causes of all cancer related deaths, belongs to the most malignant cancer types. In fact, the secondary hepatic malignancies (liver metastases) are more common than the primary ones. Almost all solid malignancies can metastasise to the liver. It is well justified that the “treat and wait” approach in the overall management of the liver cancer is not up-to-date and so creation of complex individual patient profiles is needed. This review is specifically focused on the liver metastases originating from the colorectum, breast and prostate cancer. Innovative multilevel diagnostics may procure specific panels of validated biomarkers for predisposition, development and progression of metastatic disease. Creation of the patient specific “molecular portrait” is an essential part of the diagnostic strategy. Contextually, analysis of molecular and cellular patterns in blood samples as the minimally invasive diagnostic tool and construction of diagnostic windows based on individual patient profiling is highly recommended for patient cohorts predisposed to and affected by the liver metastatic disease. Summarised information on risk assessment, predictive and prognostic panels for diagnosis and treatments of the liver metastatic disease in colorectal, breast and prostate cancer is provided.
Literatur
3.
Zurück zum Zitat Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, Grech G (2016) Breast cancer epidemic in the early 21st century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. doi:10.1007/s13277-016-5168-x Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, Grech G (2016) Breast cancer epidemic in the early 21st century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumor Biol. doi:10.​1007/​s13277-016-5168-x
7.
Zurück zum Zitat Abraham J-A, Golubnitschaja O (2016) Time for paradigm change in management of hepatocellular carcinoma: is personalised approach in horizon? Pers Med. doi:10.2217/pme-2016-0013 Abraham J-A, Golubnitschaja O (2016) Time for paradigm change in management of hepatocellular carcinoma: is personalised approach in horizon? Pers Med. doi:10.​2217/​pme-2016-0013
8.
Zurück zum Zitat Abraham J-A, Yeghiazaryan K, Golubnitschaja O (2016) Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalisation. Pers Med 13(4):347–360. doi:10.2217/pme-2016-0014 CrossRef Abraham J-A, Yeghiazaryan K, Golubnitschaja O (2016) Selective internal radiation therapy in treatment of hepatocellular carcinoma: new concepts of personalisation. Pers Med 13(4):347–360. doi:10.​2217/​pme-2016-0014 CrossRef
12.
Zurück zum Zitat Miller MC, Doyle GV, Terstappen LWMM, Miller MC, Doyle GV, Terstappen LWMM (2010) Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:e617421. doi:10.1155/2010/617421 CrossRef Miller MC, Doyle GV, Terstappen LWMM, Miller MC, Doyle GV, Terstappen LWMM (2010) Significance of circulating tumor cells detected by the cell search system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:e617421. doi:10.​1155/​2010/​617421 CrossRef
14.
Zurück zum Zitat Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray M-A, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS (2011) Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 121:784–799. doi:10.1172/JCI43757 CrossRefPubMedPubMedCentral Elkabets M, Gifford AM, Scheel C, Nilsson B, Reinhardt F, Bray M-A, Carpenter AE, Jirström K, Magnusson K, Ebert BL, Pontén F, Weinberg RA, McAllister SS (2011) Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 121:784–799. doi:10.​1172/​JCI43757 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kuznetsov HS, Marsh T, Markens BA, Castaño Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS (2012) Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2:1150–1165. doi:10.1158/2159-8290.CD-12-0216 CrossRefPubMedPubMedCentral Kuznetsov HS, Marsh T, Markens BA, Castaño Z, Greene-Colozzi A, Hay SA, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS (2012) Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2:1150–1165. doi:10.​1158/​2159-8290.​CD-12-0216 CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri M-T, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson S-J, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer E-F, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga J-Y, Michiels S (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414. doi:10.1016/S1470-2045(14)70069-5 CrossRefPubMed Bidard F-C, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Generali D, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Lebofsky R, van Laere SJ, Meier-Stiegen F, Sandri M-T, Vidal-Martinez J, Politaki E, Consoli F, Bottini A, Diaz-Rubio E, Krell J, Dawson S-J, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer E-F, Zorzino L, Johannes H, Reis-Filho JS, Pantel K, Pierga J-Y, Michiels S (2014) Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 15:406–414. doi:10.​1016/​S1470-2045(14)70069-5 CrossRefPubMed
18.
Zurück zum Zitat Hoon DSB, Kitago M, Kim J, Mori T, Piris A, Szyfelbein K, Mihm MC, Nathanson SD, Padera TP, Chambers AF, Vantyghem SA, MacDonald IC, Shivers SC, Alsarraj M, Reintgen DS, Passlick B, Sienel W, Pantel K (2006) Molecular mechanisms of metastasis. Cancer Metastasis Rev 25:203–220. doi:10.1007/s10555-006-8500-x CrossRefPubMed Hoon DSB, Kitago M, Kim J, Mori T, Piris A, Szyfelbein K, Mihm MC, Nathanson SD, Padera TP, Chambers AF, Vantyghem SA, MacDonald IC, Shivers SC, Alsarraj M, Reintgen DS, Passlick B, Sienel W, Pantel K (2006) Molecular mechanisms of metastasis. Cancer Metastasis Rev 25:203–220. doi:10.​1007/​s10555-006-8500-x CrossRefPubMed
20.
Zurück zum Zitat Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652–1658CrossRefPubMed Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652–1658CrossRefPubMed
21.
Zurück zum Zitat Solomayer EF, Diel IJ, Krempien B, Meyberg GC, Gollan C, Krainick U, Wallwiener D, Bastert G (1998) Results of iliac crest biopsies taken from 1465 patients with primary breast cancer. J Cancer Res Clin Oncol 124:44–48CrossRefPubMed Solomayer EF, Diel IJ, Krempien B, Meyberg GC, Gollan C, Krainick U, Wallwiener D, Bastert G (1998) Results of iliac crest biopsies taken from 1465 patients with primary breast cancer. J Cancer Res Clin Oncol 124:44–48CrossRefPubMed
22.
Zurück zum Zitat Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O’Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA, Velculescu VE (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154. doi:10.1126/scitranslmed.3004742 CrossRefPubMedPubMedCentral Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O’Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA, Velculescu VE (2012) Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154. doi:10.​1126/​scitranslmed.​3004742 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M (2014) Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16:440. doi:10.1186/s13058-014-0440-8 CrossRefPubMedPubMedCentral Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, Gao H, Anfossi S, Handy BC, Ueno NT, Alvarez RH, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M (2014) Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 16:440. doi:10.​1186/​s13058-014-0440-8 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O’Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483–3489. doi:10.1200/JCO.2014.56.2561 CrossRefPubMedPubMedCentral Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, Tejwani S, Schott AF, O’Rourke MA, Lew DL, Doyle GV, Gralow JR, Livingston RB, Hayes DF (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483–3489. doi:10.​1200/​JCO.​2014.​56.​2561 CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309. doi:10.1158/1078-0432.CCR-08-0872 CrossRefPubMed de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302–6309. doi:10.​1158/​1078-0432.​CCR-08-0872 CrossRefPubMed
27.
Zurück zum Zitat Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G (2015) Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg 261:164–171. doi:10.1097/SLA.0000000000000580 CrossRefPubMed Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, Bjørnbeth BA, Brudvik KW, Borgen EF, Naume B, Wiedswang G (2015) Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg 261:164–171. doi:10.​1097/​SLA.​0000000000000580​ CrossRefPubMed
28.
Zurück zum Zitat Fleischhacker M, Schmidt B (2015) Extracellular Nucleic Acids and Cancer. In: Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring (Ed: Gahan PB), Book-Series: Advances in predictive, preventive and personalised medicine (Ed.: Golubnitschaja O), Springer, Dordrecht, V.5, ISBN 978-94-017-9167-0 Fleischhacker M, Schmidt B (2015) Extracellular Nucleic Acids and Cancer. In: Circulating nucleic acids in early diagnosis, prognosis and treatment monitoring (Ed: Gahan PB), Book-Series: Advances in predictive, preventive and personalised medicine (Ed.: Golubnitschaja O), Springer, Dordrecht, V.5, ISBN 978-94-017-9167-0
29.
Zurück zum Zitat Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, Olshen AB, Gerald WL, Massagué J (2005) Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 70:149–158. doi:10.1101/sqb.2005.70.018 CrossRefPubMed Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, Olshen AB, Gerald WL, Massagué J (2005) Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 70:149–158. doi:10.​1101/​sqb.​2005.​70.​018 CrossRefPubMed
30.
Zurück zum Zitat Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès J-P, Maudelonde T, Fabre J-M, Pantel K, Alix-Panabières C (2013) Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 59:1384–1392. doi:10.1373/clinchem.2013.202846 CrossRefPubMed Denève E, Riethdorf S, Ramos J, Nocca D, Coffy A, Daurès J-P, Maudelonde T, Fabre J-M, Pantel K, Alix-Panabières C (2013) Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem 59:1384–1392. doi:10.​1373/​clinchem.​2013.​202846 CrossRefPubMed
32.
Zurück zum Zitat Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen T-M, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen T-L, Labori KJ, Lothe IMB, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17:816–826. doi:10.1038/ncb3169 CrossRefPubMed Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen T-M, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen T-L, Labori KJ, Lothe IMB, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D (2015) Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 17:816–826. doi:10.​1038/​ncb3169 CrossRefPubMed
33.
Zurück zum Zitat Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang X-F (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5:329–339. doi:10.1016/S1535-6108(04)00081-9 CrossRefPubMed Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang X-F (2004) Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5:329–339. doi:10.​1016/​S1535-6108(04)00081-9 CrossRefPubMed
35.
Zurück zum Zitat Vidal-Vanaclocha F (2011) The Tumor Microenvironment at Different Stages of Hepatic Metastasis. In: Brodt P (ed) Liver Metastasis Biol. Clin. Manag. Springer Netherlands, pp 43–87CrossRef Vidal-Vanaclocha F (2011) The Tumor Microenvironment at Different Stages of Hepatic Metastasis. In: Brodt P (ed) Liver Metastasis Biol. Clin. Manag. Springer Netherlands, pp 43–87CrossRef
36.
Zurück zum Zitat Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, Fan F, Akagi M, Ellis LM (2002) Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9:610–616CrossRefPubMed Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, Fan F, Akagi M, Ellis LM (2002) Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9:610–616CrossRefPubMed
39.
Zurück zum Zitat Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766CrossRefPubMedPubMedCentral Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL (2002) Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235:759–766CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefPubMedPubMedCentral Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Nordlinger B, Van Cutsem E, Rougier P, Köhne C-H, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G, European Colorectal Metastases Treatment Group (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European colorectal metastases treatment group. Eur J Cancer Oxf Engl 1990 43:2037–2045. doi:10.1016/j.ejca.2007.07.017 Nordlinger B, Van Cutsem E, Rougier P, Köhne C-H, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G, European Colorectal Metastases Treatment Group (2007) Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European colorectal metastases treatment group. Eur J Cancer Oxf Engl 1990 43:2037–2045. doi:10.​1016/​j.​ejca.​2007.​07.​017
42.
Zurück zum Zitat van Dam RM, Lodewick TM, van den Broek MAJ, de Jong MC, Greve JW, Jansen RLH, Bemelmans MHA, Neumann UP, Olde Damink SWM, Dejong CHC (2014) Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB 16:550–559. doi:10.1111/hpb.12181 PubMed van Dam RM, Lodewick TM, van den Broek MAJ, de Jong MC, Greve JW, Jansen RLH, Bemelmans MHA, Neumann UP, Olde Damink SWM, Dejong CHC (2014) Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases. HPB 16:550–559. doi:10.​1111/​hpb.​12181 PubMed
44.
Zurück zum Zitat Nakamura S, Suzuki S, Konno H (1999) Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J Hepatobiliary Pancreat Surg 6:16–22CrossRefPubMed Nakamura S, Suzuki S, Konno H (1999) Resection of hepatic metastases of colorectal carcinoma: 20 years’ experience. J Hepatobiliary Pancreat Surg 6:16–22CrossRefPubMed
45.
Zurück zum Zitat Suzuki S, Sakaguchi T, Yokoi Y, Kurachi K, Okamoto K, Okumura T, Tsuchiya Y, Nakamura T, Konno H, Baba S, Nakamura S (2001) Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 129:421–428. doi:10.1067/msy.2001.112486 CrossRefPubMed Suzuki S, Sakaguchi T, Yokoi Y, Kurachi K, Okamoto K, Okumura T, Tsuchiya Y, Nakamura T, Konno H, Baba S, Nakamura S (2001) Impact of repeat hepatectomy on recurrent colorectal liver metastases. Surgery 129:421–428. doi:10.​1067/​msy.​2001.​112486 CrossRefPubMed
46.
Zurück zum Zitat Malafosse R, Penna C, Sa Cunha A, Nordlinger B (2001) Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol Off J Eur Soc Med Oncol ESMO 12:887–894CrossRef Malafosse R, Penna C, Sa Cunha A, Nordlinger B (2001) Surgical management of hepatic metastases from colorectal malignancies. Ann Oncol Off J Eur Soc Med Oncol ESMO 12:887–894CrossRef
48.
52.
Zurück zum Zitat Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM (1998) Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg Off J Soc Surg Aliment Tract 2:292–298CrossRef Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM (1998) Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg Off J Soc Surg Aliment Tract 2:292–298CrossRef
53.
Zurück zum Zitat Neal CP, Mann CD, Pointen E, McGregor A, Garcea G, Metcalfe MS, Berry DP, Dennison AR (2012) Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy. J Gastrointest Surg Off J Soc Surg Aliment Tract 16:2064–2073. doi:10.1007/s11605-012-2008-1 CrossRef Neal CP, Mann CD, Pointen E, McGregor A, Garcea G, Metcalfe MS, Berry DP, Dennison AR (2012) Influence of hepatic parenchymal histology on outcome following right hepatic trisectionectomy. J Gastrointest Surg Off J Soc Surg Aliment Tract 16:2064–2073. doi:10.​1007/​s11605-012-2008-1 CrossRef
54.
Zurück zum Zitat Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A (2012) Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatol Baltim Md 56:2221–2230. doi:10.1002/hep.25935 CrossRef Reddy SK, Marsh JW, Varley PR, Mock BK, Chopra KB, Geller DA, Tsung A (2012) Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatol Baltim Md 56:2221–2230. doi:10.​1002/​hep.​25935 CrossRef
55.
Zurück zum Zitat Vauthey J-N, Pawlik TM, Ribero D, Wu T-T, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol 24:2065–2072. doi:10.1200/JCO.2005.05.3074 CrossRef Vauthey J-N, Pawlik TM, Ribero D, Wu T-T, Zorzi D, Hoff PM, Xiong HQ, Eng C, Lauwers GY, Mino-Kenudson M, Risio M, Muratore A, Capussotti L, Curley SA, Abdalla EK (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol Off J Am Soc Clin Oncol 24:2065–2072. doi:10.​1200/​JCO.​2005.​05.​3074 CrossRef
58.
Zurück zum Zitat Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 23:2038–2048. doi:10.1200/JCO.2005.00.349 CrossRef Leonard GD, Brenner B, Kemeny NE (2005) Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 23:2038–2048. doi:10.​1200/​JCO.​2005.​00.​349 CrossRef
62.
Zurück zum Zitat Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a north central cancer treatment group phase II study. J Clin Oncol Off J Am Soc Clin Oncol 23:9243–9249. doi:10.1200/JCO.2005.07.740 CrossRef Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a north central cancer treatment group phase II study. J Clin Oncol Off J Am Soc Clin Oncol 23:9243–9249. doi:10.​1200/​JCO.​2005.​07.​740 CrossRef
63.
Zurück zum Zitat Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522CrossRefPubMedPubMedCentral Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224:509–522CrossRefPubMedPubMedCentral
67.
Zurück zum Zitat De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P, Delrio P (2015) Genetics, diagnosis and management of colorectal cancer (review). Oncol Rep 34:1087–1096. doi:10.3892/or.2015.4108 PubMed De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P, Delrio P (2015) Genetics, diagnosis and management of colorectal cancer (review). Oncol Rep 34:1087–1096. doi:10.​3892/​or.​2015.​4108 PubMed
74.
75.
Zurück zum Zitat Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim S-H, Kim D-W, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T (2010) Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466:765–768. doi:10.1038/nature09171 CrossRefPubMedPubMedCentral Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim S-H, Kim D-W, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T (2010) Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466:765–768. doi:10.​1038/​nature09171 CrossRefPubMedPubMedCentral
76.
Zurück zum Zitat Watanabe M, Ohnishi Y, Inoue H, Wato M, Tanaka A, Kakudo K, Nozaki M (2014) NANOG expression correlates with differentiation, metastasis and resistance to preoperative adjuvant therapy in oral squamous cell carcinoma. Oncol Lett 7:35–40. doi:10.3892/ol.2013.1690 PubMed Watanabe M, Ohnishi Y, Inoue H, Wato M, Tanaka A, Kakudo K, Nozaki M (2014) NANOG expression correlates with differentiation, metastasis and resistance to preoperative adjuvant therapy in oral squamous cell carcinoma. Oncol Lett 7:35–40. doi:10.​3892/​ol.​2013.​1690 PubMed
80.
Zurück zum Zitat Karnes WE, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, Kim CY, McDonnell SK, Schaid DJ, Thibodeau SN (1998) Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58:5473–5477PubMed Karnes WE, Shattuck-Brandt R, Burgart LJ, DuBois RN, Tester DJ, Cunningham JM, Kim CY, McDonnell SK, Schaid DJ, Thibodeau SN (1998) Reduced COX-2 protein in colorectal cancer with defective mismatch repair. Cancer Res 58:5473–5477PubMed
81.
Zurück zum Zitat Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS (2006) Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG Island methylator phenotype in colorectal cancer. Neoplasia 8:458–464CrossRefPubMedPubMedCentral Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS (2006) Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG Island methylator phenotype in colorectal cancer. Neoplasia 8:458–464CrossRefPubMedPubMedCentral
83.
Zurück zum Zitat Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487–1495. doi:10.1038/ncb1998 CrossRefPubMed Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T (2009) The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11:1487–1495. doi:10.​1038/​ncb1998 CrossRefPubMed
85.
Zurück zum Zitat Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A (2013) MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62:1315–1326. doi:10.1136/gutjnl-2011-301846 CrossRefPubMed Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A (2013) MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 62:1315–1326. doi:10.​1136/​gutjnl-2011-301846 CrossRefPubMed
88.
Zurück zum Zitat Golubnitschaja O, Yeghiazaryan K, Stricker H, Trog D, Schild HH, Berliner L (2016) Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer 16(1):357. doi:10.1186/s12885-016-2382-2 CrossRefPubMedPubMedCentral Golubnitschaja O, Yeghiazaryan K, Stricker H, Trog D, Schild HH, Berliner L (2016) Patients with hepatic breast cancer metastases demonstrate highly specific profiles of matrix metalloproteinases MMP-2 and MMP-9 after SIRT treatment as compared to other primary and secondary liver tumours. BMC Cancer 16(1):357. doi:10.​1186/​s12885-016-2382-2 CrossRefPubMedPubMedCentral
89.
Zurück zum Zitat Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L (1997) Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75:698–702CrossRefPubMedPubMedCentral Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, Faggiuolo R, Cannone R, Farris A, Destefanis M, Moro G, Deltetto F, Dogliotti L (1997) Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer 75:698–702CrossRefPubMedPubMedCentral
93.
Zurück zum Zitat Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol Off J Eur Soc Med Oncol ESMO 25:1901–1914. doi:10.1093/annonc/mdu042 CrossRef Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol Off J Eur Soc Med Oncol ESMO 25:1901–1914. doi:10.​1093/​annonc/​mdu042 CrossRef
94.
Zurück zum Zitat Weinrich M, Weiß Christel, Schuld J, Rau BM (2014) Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. HPB Surg 2014:e893829. doi:10.1155/2014/893829 CrossRef Weinrich M, Weiß Christel, Schuld J, Rau BM (2014) Liver resections of isolated liver metastasis in breast cancer: results and possible prognostic factors. HPB Surg 2014:e893829. doi:10.​1155/​2014/​893829 CrossRef
95.
Zurück zum Zitat Girotra S, Yeghiazaryan K, Golubnitschaja O (2016) Potential biomarker panels in overall breast cancer management: advancements by multi-level diagnostics. Pers Med. doi:10.2217/pme-2016-0020 Girotra S, Yeghiazaryan K, Golubnitschaja O (2016) Potential biomarker panels in overall breast cancer management: advancements by multi-level diagnostics. Pers Med. doi:10.​2217/​pme-2016-0020
96.
Zurück zum Zitat Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH (2013) Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J 4:6. doi:10.1186/1878-5085-4-6 CrossRefPubMedPubMedCentral Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH (2013) Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J 4:6. doi:10.​1186/​1878-5085-4-6 CrossRefPubMedPubMedCentral
98.
Zurück zum Zitat Kimbung S, Kovács A, Bendahl P-O, Malmström P, Fernö M, Hatschek T, Hedenfalk I (2014) Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol 8:119–128. doi:10.1016/j.molonc.2013.10.002 CrossRefPubMed Kimbung S, Kovács A, Bendahl P-O, Malmström P, Fernö M, Hatschek T, Hedenfalk I (2014) Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences. Mol Oncol 8:119–128. doi:10.​1016/​j.​molonc.​2013.​10.​002 CrossRefPubMed
102.
Zurück zum Zitat Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE (2015) Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol 141:243–254. doi:10.1007/s00432-014-1824-y CrossRefPubMed Henry C, Quadir A, Hawkins NJ, Jary E, Llamosas E, Kumar D, Daniels B, Ward RL, Ford CE (2015) Expression of the novel Wnt receptor ROR2 is increased in breast cancer and may regulate both β-catenin dependent and independent Wnt signalling. J Cancer Res Clin Oncol 141:243–254. doi:10.​1007/​s00432-014-1824-y CrossRefPubMed
104.
Zurück zum Zitat Bleckmann A, Conradi L-C, Menck K, Schmick NA, Schubert A, Rietkötter E, Arackal J, Middel P, Schambony A, Liersch T, Homayounfar K, Beißbarth T, Klemm F, Binder C, Pukrop T (2016) β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. Clin Exp Metastasis. doi:10.1007/s10585-016-9780-3 PubMedPubMedCentral Bleckmann A, Conradi L-C, Menck K, Schmick NA, Schubert A, Rietkötter E, Arackal J, Middel P, Schambony A, Liersch T, Homayounfar K, Beißbarth T, Klemm F, Binder C, Pukrop T (2016) β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. Clin Exp Metastasis. doi:10.​1007/​s10585-016-9780-3 PubMedPubMedCentral
105.
Zurück zum Zitat Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 31:578–583CrossRefPubMed Bubendorf L, Schöpfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1589 patients. Hum Pathol 31:578–583CrossRefPubMed
108.
Zurück zum Zitat Fowler JE, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA (2000) Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5–9.9 ng./ml. J Urol 163:1467–1470CrossRefPubMed Fowler JE, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA (2000) Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5–9.9 ng./ml. J Urol 163:1467–1470CrossRefPubMed
109.
Zurück zum Zitat Moul JW, Douglas TH, McCarthy WF, McLeod DG (1996) Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 155:1667–1673CrossRefPubMed Moul JW, Douglas TH, McCarthy WF, McLeod DG (1996) Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol 155:1667–1673CrossRefPubMed
110.
Zurück zum Zitat Drake CG (2014) Visceral metastases and prostate cancer treatment: “die hard”, “tough neighborhoods”, or “evil humors”? Oncol (Williston Park NY) 28:974–980 Drake CG (2014) Visceral metastases and prostate cancer treatment: “die hard”, “tough neighborhoods”, or “evil humors”? Oncol (Williston Park NY) 28:974–980
114.
Zurück zum Zitat Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84:9233–9237CrossRefPubMedPubMedCentral Yoshimura T, Matsushima K, Tanaka S, Robinson EA, Appella E, Oppenheim JJ, Leonard EJ (1987) Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 84:9233–9237CrossRefPubMedPubMedCentral
115.
Zurück zum Zitat Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang X-D, Gudas JM, Bar-Eli M (2002) Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161:125–134CrossRefPubMedPubMedCentral Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang X-D, Gudas JM, Bar-Eli M (2002) Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 161:125–134CrossRefPubMedPubMedCentral
116.
Zurück zum Zitat Goodman OB, Flaig TW, Molina A, Mulders PFA, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI (2014) Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 17:34–39. doi:10.1038/pcan.2013.41 CrossRefPubMed Goodman OB, Flaig TW, Molina A, Mulders PFA, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI (2014) Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 17:34–39. doi:10.​1038/​pcan.​2013.​41 CrossRefPubMed
117.
Zurück zum Zitat Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest oncology group trial 9346 (INT-0162). J Clin Oncol 24:3984–3990. doi:10.1200/JCO.2006.06.4246 CrossRefPubMed Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest oncology group trial 9346 (INT-0162). J Clin Oncol 24:3984–3990. doi:10.​1200/​JCO.​2006.​06.​4246 CrossRefPubMed
118.
119.
Zurück zum Zitat Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A, Erler JT (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522(7554):106–110. doi:10.1038/nature14492 CrossRefPubMedPubMedCentral Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, Huggins ID, Lang G, Linding R, Gartland A, Erler JT (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522(7554):106–110. doi:10.​1038/​nature14492 CrossRefPubMedPubMedCentral
120.
Zurück zum Zitat Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, Lushchyk U, Grech G, Konieczka K (2016) Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J 7(Suppl 1):A25 Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, Lushchyk U, Grech G, Konieczka K (2016) Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J 7(Suppl 1):A25
Metadaten
Titel
Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes
verfasst von
Olga Golubnitschaja
Krishna Chander Sridhar
Publikationsdatum
19.08.2016
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2016
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9816-8

Weitere Artikel der Ausgabe 8/2016

Clinical & Experimental Metastasis 8/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.